A Phase 3 interventional study of DOR/ISL and BIC/FTC/TAF in HIV Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 89 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in HIV Infections by Merck & Co., Inc — 1 open to participants now, 2 under way, 1 of them phase 3. HIV Infections · Merck & Co., Inc.
Among the 75 studies in HIV Infections by Merck & Co., Inc, this one is the 6th largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2020, is one of 21 in phase 3, and was the 71st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →1 of the 75 studies in HIV Infections by Merck & Co., Inc is open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC
Ages up to 18
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 643 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 163 across the 66 interventional studies, 357 across the 6 observational. Of the 66 that completed or were terminated, 29 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 75 studies in HIV Infections by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of a switch to Doravirine/Islatravir (DOR/ISL) (MK-8591A) (a fixed dose combination of doravirine 100 mg and islatravir 0.75 mg) in participants living with human immunodeficiency virus-1 (HIV-1) virologically suppressed on a regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that a switch to DOR/ISL (MK-8591A) will be non-inferior to continued treatment with BIC/FTC/TAF as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48. Participants who benefit from their assigned intervention (as determined by investigator) will be able to continue treatment through a 24-week study extension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.
Drug: DOR/ISL · Drug: Placebo to BIC/FTC/TAF
Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.
Drug: BIC/FTC/TAF · Drug: Placebo to FDC DOR/ISL
Drug pages: Doravirine · Islatravir
100 mg DOR/ 0.75 ISL FDC single tablet taken orally once daily
Also known as: MK-8591A
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily
Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily
Placebo to FDC DOR/ISL in a single tablet taken orally, once daily
Also known as: Placebo to MK-8591A
Percentage of Participants With Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 Copies/mL at Week 48
The Abbott RealTime polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the primary outcome measure, the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
Time frame: Week 48
Percentage of Participants With One or More Adverse Events (AEs) up to Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE up to week 48 is presented.
Time frame: Up to 48 weeks
Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE up to week 48 is presented.
Time frame: Up to 48 weeks
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
Time frame: Week 144
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48, is presented using the FDA snapshot missing data approach.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96, is presented using the FDA snapshot missing data approach.
Time frame: Week 96
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
Time frame: Week 144
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA \<40 copies/mL at Week 144, is presented using the FDA snapshot missing data approach.
Time frame: Week 144
Mean Change From Baseline in Cluster of Differentiation-positive (CD4+) T-cell Count at Week 48
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 48 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 48 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.
Time frame: Baseline and Week 48
Mean Change From Baseline in CD4+ T-cell Count at Week 96
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 96 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 96 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.
Time frame: Baseline and Week 96
Mean Change From Baseline in CD4+ T-cell Count at Week 144
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 144 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 144 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.
Time frame: Baseline and Week 144
Number of Participants With Viral Drug Resistance-associated Substitutions at Week 48
Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL having genotypic or phenotypic evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance is presented.
Time frame: Week 48
Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 96
Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 96 is presented.
Time frame: Week 96
Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 144
Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 144 is presented.
Time frame: Week 144
Change From Baseline in Body Weight at Week 48
Body weight was measured and recorded at baseline and week 48. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 48 is presented.
Time frame: Baseline and Week 48
Change From Baseline in Body Weight at Week 96
Body weight was measured and recorded at baseline and week 96. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 96 is presented.
Time frame: Baseline and Week 96
Change From Baseline in Body Weight at Week 144
Body weight was measured and recorded at baseline and week 144. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 144 is presented.
Time frame: Baseline and Week 144
Percentage of Participants With One or More AEs
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced at least one or more AEs is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module.
Time frame: Up to approximately 55 months
Percentage of Participants Who Discontinued Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module.
Time frame: Up to approximately 40 months
Adult participants living with human immunodeficiency virus-1 (HIV-1) who have been virologically suppressed for ≥3 months and receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) with no history of treatment failure were enrolled.
| Milestone | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Started | 322 | 321 |
| Treated | 322 | 319 |
| Completed | 224 | 211 |
| Not completed | 98 | 110 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Lost to follow-up | 5 | 8 |
| Withdrew: Physician decision | 18 | 7 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Sponsor decision | 11 | 39 |
| Withdrew: Withdrawal by subject | 56 | 40 |
| Withdrew: Other | 6 | 15 |
| Milestone | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Started | 132 | 131 |
| Completed | 10 | 2 |
| Not completed | 122 | 129 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Sponsor decision | 91 | 124 |
| Withdrew: Withdrawal by subject | 28 | 2 |
| Withdrew: Other | 0 | 1 |
The Abbott RealTime polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the primary outcome measure, the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| HIV-1 RNA ≥50 Copies/mL | 0.6 | 0.3 |
| No Virologic Data in Window | 5.6 | 5.3 |
| HIV-1 RNA <50 Copies/mL | 93.8 | 94.4 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE up to week 48 is presented.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With One or More Adverse Events (AEs) up to Week 48 | 71.1 | 74.6 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE up to week 48 is presented.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48 | 2.5 | 2.5 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| HIV-1 RNA ≥50 Copies/mL | 0.6 | 0.3 |
| No Virologic Data in Window | 14.3 | 8.8 |
| HIV-1 RNA <50 Copies/mL | 85.1 | 90.9 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| HIV-1 RNA ≥50 Copies/mL | 0.9 | 1.3 |
| No Virologic Data in Window | 47.2 | 33.2 |
| HIV-1 RNA <50 Copies/mL | 51.9 | 65.5 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| HIV-1 RNA <50 Copies/mL | 93.8 | 94.4 |
| No Virologic Data in Window | 5.6 | 5.3 |
| HIV-1 RNA ≥50 Copies/mL | 0.6 | 0.3 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48, is presented using the FDA snapshot missing data approach.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48 | 93.2 | 94.0 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| HIV-1 RNA <50 copies/mL | 85.1 | 90.9 |
| No Virologic Data in Window | 14.3 | 8.8 |
| HIV-1 RNA ≥50 copies/mL | 0.6 | 0.3 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96, is presented using the FDA snapshot missing data approach.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96 | 84.8 | 90.9 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| HIV-1 RNA <50 copies/mL | 51.9 | 65.5 |
| No Virologic Data in Window | 47.2 | 33.2 |
| HIV-1 RNA ≥50 copies/mL | 0.9 | 1.3 |
The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA \<40 copies/mL at Week 144, is presented using the FDA snapshot missing data approach.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144 | 51.9 | 65.5 |
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 48 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 48 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.
| cells/mm^3 | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Mean Change From Baseline in Cluster of Differentiation-positive (CD4+) T-cell Count at Week 48 | -19.66 (-39.78 to 0.45) | 40.51 (20.66 to 60.36) |
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 96 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 96 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.
| cells/mm^3 | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Mean Change From Baseline in CD4+ T-cell Count at Week 96 | 5.36 (-19.71 to 30.42) | 62.67 (40.44 to 84.90) |
Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and 144 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 144 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline.
| cells/mm^3 | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Mean Change From Baseline in CD4+ T-cell Count at Week 144 | 0.48 (-28.69 to 29.64) | 66.25 (38.78 to 93.73) |
Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL having genotypic or phenotypic evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance is presented.
| Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Number of Participants With Viral Drug Resistance-associated Substitutions at Week 48 | 0 | — |
Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 96 is presented.
| Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 96 | 0 | — |
Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 144 is presented.
| Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Number of Participants With Evidence of Viral Drug Resistance-associated Substitutions at Week 144 | 0 | — |
Body weight was measured and recorded at baseline and week 48. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 48 is presented.
| kilogram (kg) | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Change From Baseline in Body Weight at Week 48 | 0.23 ± 4.19 | 0.55 ± 4.40 |
Body weight was measured and recorded at baseline and week 96. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 96 is presented.
| kilogram (kg) | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Change From Baseline in Body Weight at Week 96 | 0.29 ± 5.33 | 0.72 ± 5.72 |
Body weight was measured and recorded at baseline and week 144. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 144 is presented.
| kilogram (kg) | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Change From Baseline in Body Weight at Week 144 | 0.63 ± 6.67 | 0.84 ± 6.41 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced at least one or more AEs is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants With One or More AEs | 96.3 | 94.4 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module.
| Percentage of Participants | DOR/ISL | BIC/FTC/TAF |
|---|---|---|
| Percentage of Participants Who Discontinued Study Intervention Due to an AE | 22.0 | 6.9 |
Collected over Up to approximately 55 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DOR/ISL: Base Study Week 0 - Week 48 | 0/322 (0%) | 14/322 (4.3%) | 85/322 (26.4%) |
| DOR/ISL: Base Study Week 48-Week 96 | 2/305 (0.7%) | 19/305 (6.2%) | 104/305 (34.1%) |
| DOR/ISL: Base Study Week 96-Week 144 | 0/266 (0%) | 7/266 (2.6%) | 151/266 (56.8%) |
| BIC/FTC/TAF: Base Study Week 0 - Week 48 | 0/321 (0%) | 16/319 (5%) | 93/319 (29.2%) |
| BIC/FTC/TAF: Base Study Week 48 - Week 96 | 0/301 (0%) | 11/301 (3.7%) | 86/301 (28.6%) |
| BIC/FTC/TAF: Base Study Week 96 - Week 144 | 0/281 (0%) | 6/281 (2.1%) | 101/281 (35.9%) |
| DOR/ISL: Open-Label Extension Week 144-Week 168 | 0/132 (0%) | 0/132 (0%) | 34/132 (25.8%) |
| BIC/FTC/TAF: Open-Label Extension Week 144 - Week 168 | 0/131 (0%) | 1/131 (0.8%) | 13/131 (9.9%) |
| DOR/ISL: Post-Treatment Follow-Up | 0/196 (0%) | 3/196 (1.5%) | 14/196 (7.1%) |
| BIC/FTC/TAF: Post-Treatment Follow-Up | 0/152 (0%) | 0/152 (0%) | 0/152 (0%) |
| Event | DOR/ISL: Base Study Week 0 - Week 48 | DOR/ISL: Base Study Week 48-Week 96 | DOR/ISL: Base Study Week 96-Week 144 | BIC/FTC/TAF: Base Study Week 0 - Week 48 | BIC/FTC/TAF: Base Study Week 48 - Week 96 | BIC/FTC/TAF: Base Study Week 96 - Week 144 | DOR/ISL: Open-Label Extension Week 144-Week 168 | BIC/FTC/TAF: Open-Label Extension Week 144 - Week 168 | DOR/ISL: Post-Treatment Follow-Up | BIC/FTC/TAF: Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/322 | 0/305 | 0/266 | 0/319 | 0/301 | 1/281 | 0/132 | 1/131 | 0/196 | 0/152 |
| Acute myocardial infarctionCardiac disorders | 2/322 | 1/305 | 1/266 | 0/319 | 0/301 | 0/281 | 0/132 | 0/131 | 0/196 | 0/152 |
| Myocardial infarctionCardiac disorders | 0/322 | 0/305 | 0/266 | 0/319 | 0/301 | 0/281 | 0/132 | 0/131 | 1/196 | 0/152 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/322 | 0/305 | 0/266 | 1/319 | 0/301 | 0/281 | 0/132 | 0/131 | 1/196 | 0/152 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/322 | 0/305 | 0/266 | 1/319 | 0/301 | 0/281 | 0/132 | 0/131 | 1/196 | 0/152 |
| Atrial fibrillationCardiac disorders | 0/322 | 1/305 | 1/266 | 0/319 | 0/301 | 0/281 | 0/132 | 0/131 | 0/196 | 0/152 |
| ColitisGastrointestinal disorders | 0/322 | 1/305 | 1/266 | 0/319 | 0/301 | 1/281 | 0/132 | 0/131 | 0/196 | 0/152 |
| Pyelonephritis acuteInfections and infestations | 0/322 | 0/305 | 1/266 | 0/319 | 0/301 | 0/281 | 0/132 | 0/131 | 0/196 | 0/152 |
| Tibia fractureInjury, poisoning and procedural complications | 0/322 | 0/305 | 1/266 | 0/319 | 0/301 | 0/281 | 0/132 | 0/131 | 0/196 | 0/152 |
| MyositisMusculoskeletal and connective tissue disorders | 0/322 | 0/305 | 1/266 | 0/319 | 0/301 | 0/281 | 0/132 | 0/131 | 0/196 | 0/152 |
| Event | DOR/ISL: Base Study Week 0 - Week 48 | DOR/ISL: Base Study Week 48-Week 96 | DOR/ISL: Base Study Week 96-Week 144 | BIC/FTC/TAF: Base Study Week 0 - Week 48 | BIC/FTC/TAF: Base Study Week 48 - Week 96 | BIC/FTC/TAF: Base Study Week 96 - Week 144 | DOR/ISL: Open-Label Extension Week 144-Week 168 | BIC/FTC/TAF: Open-Label Extension Week 144 - Week 168 | DOR/ISL: Post-Treatment Follow-Up | BIC/FTC/TAF: Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|
| Lymphocyte count decreasedInvestigations | 1/322 | 32/305 | 86/266 | 0/319 | 8/301 | 28/281 | 21/132 | 6/131 | 0/196 | 0/152 |
| CD4 lymphocytes decreasedInvestigations | 1/322 | 28/305 | 63/266 | 0/319 | 4/301 | 28/281 | 15/132 | 6/131 | 0/196 | 0/152 |
| COVID-19Infections and infestations | 19/322 | 40/305 | 33/266 | 18/319 | 45/301 | 46/281 | 2/132 | 0/131 | 5/196 | 0/152 |
| HeadacheNervous system disorders | 26/322 | 14/305 | 3/266 | 22/319 | 6/301 | 1/281 | 1/132 | 0/131 | 1/196 | 0/152 |
| DiarrhoeaGastrointestinal disorders | 8/322 | 7/305 | 7/266 | 20/319 | 7/301 | 2/281 | 2/132 | 0/131 | 2/196 | 0/152 |
| NasopharyngitisInfections and infestations | 9/322 | 11/305 | 16/266 | 3/319 | 11/301 | 10/281 | 1/132 | 3/131 | 4/196 | 0/152 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/322 | 8/305 | 9/266 | 19/319 | 14/301 | 8/281 | 1/132 | 0/131 | 1/196 | 0/152 |
| Back painMusculoskeletal and connective tissue disorders | 13/322 | 9/305 | 9/266 | 17/319 | 6/301 | 8/281 | 0/132 | 1/131 | 1/196 | 0/152 |
| HypertensionVascular disorders | 6/322 | 3/305 | 5/266 | 16/319 | 6/301 | 3/281 | 1/132 | 1/131 | 0/196 | 0/152 |
| Age, Continuous(Years) | DOR/ISL | BIC/FTC/TAF | Total |
|---|---|---|---|
| Mean | 47.6 ± 12.6 | 48.0 ± 11.8 | 47.8 ± 12.2 |
| Sex: Female, Male(Participants) | DOR/ISL | BIC/FTC/TAF | Total |
|---|---|---|---|
| Female | 105 | 78 | 183 |
| Male | 217 | 243 | 460 |
| Ethnicity (NIH/OMB)(Participants) | DOR/ISL | BIC/FTC/TAF | Total |
|---|---|---|---|
| Hispanic or Latino | 64 | 55 | 119 |
| Not Hispanic or Latino | 256 | 261 | 517 |
| Unknown or Not Reported | 2 | 5 | 7 |
| Race (NIH/OMB)(Participants) | DOR/ISL | BIC/FTC/TAF | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 2 | 5 |
| Asian | 14 | 13 | 27 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 59 | 56 | 115 |
| White | 239 | 240 | 479 |
| More than one race | 5 | 7 | 12 |
| Unknown or Not Reported | 0 | 3 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Feb 2020 to primary completion in Aug 2021, 18 months.
Results were first posted in Aug 2022, 11 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 18 months is below that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Islatravir